The Policy of Subsidy Elimination from Currency Allocated to Pharmaceutical Sector in Iran; Concerns of Patients, Payers, and Industry
Abstract
Background: Pharmaceutical sector in Iran is a generic-based market in which local manufacturers supply over 98% of sales volume and 85% of sales value, according to the latest published data by the Iran Food and Drug Administration (IFDA) in 2021. Share of imported generics and original brands from the market has been decreasing due to Iran MOH's cost-containment and localization support policies Methods: The generalized conditional heterogeneous variance self-regression econometric method (GARCH-M) is used to analyze the data and estimate the actual exchange rate uncertainty index. Results: Strict and unfair cost-plus approach in repricing could cause margin loss for local companies and put the sustainability of the whole local generic industry at risk. Conclusion: Given the consequences of subsidized currency on the pharmaceutical and healthcare systems, the government's decision to eliminate subsidies from money seems rational and defensible. However, all concerns of different stakeholders must be heard and addressed before the implantation of this policy. With good budget raise for health insurance from subsidy elimination revenues (cross-subsidization) sources, the government should ensure that this policy will not burden any unaffordable cost or loss to either patients or industry. In addition, agility in the pricing, budgeting, and reimbursement processes is a critical success factor for MOH and IFDA to avoid harm to stakeholders.Cheraghali A. Trends in Iran pharmaceutical market. Iran J Pharm Res. 2017; 16(1):1-7.
Zaboli P, Hashemi-Meshkini A, Varmaghani M, Gholami H, Vazirian I, Zekri HS, et al. Pharmaceutical laws and regulations in Iran: An overview. J Res Pharm Pract. 2016; 5(3):155-61. [DOI:10.4103/2279-042X.185709]
Ashrafi Shahmirzadi N, Abdollahiasl A, Kebriaeezadeh A. Assessment of influential variables in the pricing of locally manufactured pharmaceuticals: Current challenging situation in Iran. Iran J Pharm Res. 2021; 20(1):283-95. [DOI:10.22037/ijpr.2020.112288.13662]
Yousefi N, Moradi N, Dinarvand R, Ghiasi G, Inanloo H, Peiravian F. Policies to improve access to pharmaceutical products in shortage: The experience of Iran food and drug administration. Daru. 2019; 27(1):169-77. [DOI:10.1007/s40199-019-00259-2]
Eghtesad Online. Iran gov’t to continue supply of subsidized essential goods [Internet]. 2020 [updated October 2022]. Available from: Iran Gov’t to Continue Supply of Subsidized Essential Goods (2020/09/28) Online available at: https://www.en.eghtesadonline.com/Section-iran-economy-67/33640-iran-gov-to-continue-supply-of-subsidized-essential-goods
Central Bank of the Islamic Republic of Iran. Online available at: http://www.sanarate.ir/Default.aspx
Setayesh S, Mackey TK. Addressing the impact of economic sanctions on Iranian drug shortages in the joint comprehensive plan of action: Promoting access to medicines and health diplomacy. Global Health. 2016; 12(1):31. [DOI:10.1186/s12992-016-0168-6]
Cheraghali AM. Impacts of international sanctions on Iranian pharmaceutical market. Daru. 2013; 21(1):64. [DOI:10.1186/20082231-21-64]
Kheirandish M, Varahrami V, Kebriaeezade A, Cheraghali AM. Impact of economic sanctions on access to noncommunicable diseases medicines in the Islamic Republic of Iran. East Mediterr Health J. 2018; 24(1):42-51. [DOI:10.26719/2018.24.1.42]
Hosseini SA. Impact of sanctions on procurement of medicine and medical devices in Iran; A technical response. Arch Iran Med. 2013; 16(12):736-8.
Jaberidoost M, Olfat L, Hosseini A, Kebriaeezadeh A, Abdollahi M, Alaeddini M, et al. Pharmaceutical supply chain risk assessment in Iran using analytic hierarchy process (AHP) and simple additive weighting (SAW) methods. J Pharm Policy Pract. 2015; 8(1):9. [DOI:10.1186/s40545-015-0029-3]
Bastani P, Dehghan Z, Kashfi SM, Dorosti H, Mohammadpour M, Mehralian G. Challenge of politico-economic sanctions on pharmaceutical procurement in Iran: A qualitative study. Iran J Med Sci. 2022; 47(2):152-61. [DOI:10.30476/IJMS.2021.89901.2078]
Masoumi M, Ebadi Fard Azar F, RezaPour A, Mehrara M. Economic and non-economic determinants of Iranian pharmaceutical companies’ financial performance: An empirical study. BMC Health Serv Res. 2019; 19(1):1011. [DOI:10.1186/s12913-019-4735-4]
Masoomzadeh M, Shirafkan M. The effect of exchange rate on the Iran’s pharmaceutical industry balance: Vector error correction approach. Journal Healthc Manage. 2017; 8(3):17-28.
Ahmadiani S, Nikfar S. Challenges of access to medicine and the responsibility of pharmaceutical companies: A legal perspective. Daru. 2016; 24(1):13. [DOI:10.1186/s40199-016-0151-z]
Zarif-Yeganeh M, Kargar M, Rashidian A, Jafarzadeh Kohneloo A, Gholami K. Out of pocket payment and affordability of medication for geriatric patients in Tehran, Iran. Iran J Public Health. 2019; 48(6):1124-32. [DOI:10.18502/ijph.v48i6.2924]
Vasheghani Farahani A, Rasekh H, Najafi S, Rahimi F, Akbari M, SalehniaF,et al. Evaluationof affordabilityandimpoverishment effect of cardiovascular medicines in Iran. Iran J Pharm Sci. 2018; 14(2):65-74. [DOI:10.22034/IJPS.2018.33739]
Varmaghani M,Hashemi-MeshkiniA,AbdollahiaslA,HeidariE, Zekri H-S, Yaghoubifard S, et al. An overview topharmaceuti-cal financing in Iran. J Pharmacoeconomics Pharm Manage. 2016; 2(1/2):45-9.
Zarei L, Peymani P, Moradi N, Kheirandish M, Mirjalili M, Zare M. Affordability of medication therapy in diabetic patients: A scenar- io-based assessment in Iran’s health system context. Int J Health Policy Manag. 2022; 11(4):443-52. [DOI:10.34172/ijhpm.2020.152]
Delpasand M, Olyaaeemanesh A, Jaafaripooyan E, Abdollahiasl A, Davari M, Kazemi Karyani A. Eliciting the public preferences for pharmaceutical subsidy in Iran: A discrete choice experiment study. J Pharm Policy Pract. 2021; 14(1):59. [DOI:10.1186/s40545-021- 00345-4]
Rahimi F, Rasekh HR, Abbasian E, Peiravian F. A new approach to pharmaceutical pricing based on patients’ willingness to pay. Trop Med Int Health. 2018; 23(12):1326-31. [DOI:10.1111/tmi.13157]
Ebadi Fardazar F, Sarabi Asiabar A, Safari H, Asgari M, Saber A, Ebadi Fard Azar AA. Policy analysis of Iranian pharmaceutical sector; A qualitative study. Risk Manag Healthc Policy. 2019; 12:199-208. [DOI:10.2147/RMHP.S209318]
Hashemi-Meshkini A. Making the public health and industrial objectives balanced; The big challenge of Iran’s food and drug organization. Iran J Public Health. 2014; 43(5):693-5.
| Files | ||
| Issue | Vol 8 No 4 (2022) | |
| Section | Original Article(s) | |
| Keywords | ||
| Subsidy Elimination Policy Pharmaceutical industry | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
